

PREFERRED SPECIALTY MANAGEMENT POLICY

- POLICY:** Somatostatin Analogs – Octreotide Immediate-Release Products Preferred Specialty Management Policy
- Bynfezia Pen™ (immediate-release octreotide acetate subcutaneous injection – Sun)
 - Sandostatin® (immediate-release octreotide acetate subcutaneous or intravenous injection – Novartis, generic)

REVIEW DATE: 05/22/2024

OVERVIEW

Octreotide acetate immediate-release injection products are somatostatin analogs indicated for the following uses:¹⁻³

- **Acromegaly**, to reduce blood levels of growth hormone and insulin-like growth factor 1 in adults with acromegaly who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses.
- **Carcinoid tumors**, in adults with severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
- **Vasoactive intestinal peptide (VIP) tumors**, in adults with profuse watery diarrhea associated with VIP-secreting tumors.

Table 1 illustrates availability, administration, and storage for each product.

Table 1. Availability and Storage for Bynfezia Pen, Sandostatin, and Generic Octreotide Injection.¹⁻³

POLICY STATEMENT

This Preferred Specialty Management program has been developed to encourage the use of Preferred Product. For all medications (Preferred and Non-Preferred), the patient is required to meet the standard *Somatostatin Analogs – Octreotide Immediate-Release Products Prior Authorization Policy* criteria. The program directs the patient to try one Preferred Product prior to the approval of a Non-Preferred Product. Requests for Non-Preferred Products will also be reviewed using the exception criteria (below). All approvals are provided for the duration noted below. If the patient meets the standard *Somatostatin Analogs – Octreotide Immediate-Release Products Prior Authorization Policy* criteria, but has not tried a Preferred Product, approval for a Preferred Product will be authorized.

Automation: None.

Preferred Products: Octreotide acetate immediate-release injection
Non-Preferred Products: Bynfezia Pen, Sandostatin

RECOMMENDED EXCEPTION CRITERIA

REFERENCES

1. Bynfezia Pen™ subcutaneous injection [prescribing information]. Cranbury, NJ: Sun Pharmaceutical; April 2020.
2. Sandostatin® subcutaneous or intravenous injection [prescribing information]. East Hanover, NJ: Novartis; November 2023.
3. Octreotide subcutaneous injection [prescribing information]. Mahwah, NJ: Glenmark; October 2023.